title: Erythropoietin dose requirements when converting from subcutaneous to intravenous administration among patients on hemodialysis.
abstract: BACKGROUND
  The optimal route for administration of exogenous erythropoietin remains controversial, particularly after the increased incidence in pure red cell aplasia. In Canada, the majority of hemodialysis units have converted to the intravenous route for administration of erythropoietin to potentially decrease the risk of pure red cell aplasia.
  
  
  OBJECTIVE
  To compare the difference in the weight-adjusted, weekly erythropoietin dose (units/kg/wk) administered by the subcutaneous compared with the intravenous route in a chronic hemodialysis population followed for 12 months.
  
  
  METHODS
  This prospective cohort study recruited patients receiving subcutaneous erythropoietin for at least 3 months while undergoing dialysis in a tertiary care hemodialysis program. Participants were switched to intravenous erythropoietin, and the average weekly dose was recorded at 1, 2, 3, 6, and 12 months. Anemia management and hemoglobin, iron, and delivered dialysis dose targets remained constant throughout the study.
  
  
  RESULTS
  The erythropoietin dose increased by 24.5 units/kg/wk (95% CI 12.7 to 36.3; p < 0.001), representing a 20.2% increase (95% CI 10.5% to 29.9%; p < 0.001) 12 months after conversion from the subcutaneous to intravenous route of administration. Both patients with and without residual renal function at baseline required a significant increase in the intravenous dose.
  
  
  CONCLUSIONS
  A 20.2% increase in erythropoietin dose was required to maintain hemoglobin targets between 11 and 12 g/dL after conversion from a subcutaneous to intravenous formulation. Healthcare funding agencies need to reexamine the cost benefit of using intravenous erythropoietin in the hemodialysis population with a low incidence of pure red cell aplasia.
authors.affiliation: University of Western Ontario, London Health Sciences Centre--Victoria Hospital, London, Ontario, Canada. louise.moist@lhsc.on.ca
authors.forename: Louise M
authors.initials: LM
authors.lastname: Moist
authors.forename: Norm
authors.initials: N
authors.lastname: Muirhead
authors.forename: Lori D
authors.initials: LD
authors.lastname: Wazny
authors.forename: Kerri L
authors.initials: KL
authors.lastname: Gallo
authors.forename: A Paul
authors.initials: AP
authors.lastname: Heidenheim
authors.forename: Andrew A
authors.initials: AA
authors.lastname: House
mesh_terms: D000368:Aged; D000740:Anemia / Q000097:blood / Q000209:etiology / Q000517:prevention & control; D018592:Cross-Over Studies; D004305:Dose-Response Relationship, Drug; D004921:Erythropoietin / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D007676:Kidney Failure, Chronic / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011994:Recombinant Proteins; D006435:Renal Dialysis / Q000009:adverse effects*
chemical_list: D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin